M-CSF Rat anti-Mouse, Clone: 131621, Invitrogen
Rat Monoclonal Antibody
Manufacturer: Invitrogen MA523863
In sandwich ELISAs, no cross-reactivity with recombit human M-CSF, recombit mouse (rm) SCF, rmFlt-3 Ligand, rmG-CSF, and rmGM-CSF is observed. Reconstitute at 0.5 mg/mL in sterile PBS. Endoxin level is <0.10 EU per 1 µg of the antibody by the LAL method.M-CSF (Macrophage colony-stimulating factor, CSF-1) is a survival factor essential for the proliferation and development of monocytes, macrophages, and osteoclast progenitor cells. M-CSF also induces VEGF (vascular endothelial growth factor) secretion by macrophages, thereby mediating mobilization of endothelial progenitor cells and neovascularization. M-CSF is present as several bioactive isoforms that differ in potency and stability. The full-length protein is synthesized as a membrane-spanning protein that can be expressed on the cell surface or further cleaved and modified in the secretory vesicle. Further, M-CSF is a disulfide-bonded homodimer which is processed into one of two isoforms, a glycoprotein or a proteoglycan that has been modified by the addition of chondroitin sulfate to each subunit. Binding of M-CSF to its receptor, c-Fms (CSF-1R or CD115) induces dimerization of the receptor followed by internalization and degradation of the complex. Functionally, M-CSF is known to stimulate differentiation of hematopoietic stem cells to monocyte-macrophage cell populations in culture. M-CSF acts through the CSF receptor 1. Although human M-CSF shows activity on mouse cells, mouse CSF shows no activity on human cells.
|PBS with 5% trehalose and No Preservative|
|MCSF, MGC31930, CSF1|
|-20° C, Avoid Freeze/Thaw Cycles|
|E. coli-derived recombit mouse M-CSF Lys33-Glu262 (predicted)|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok